Pepperz

Peptide

Semaglutide

Semaglutide is used or studied for weight loss; glycemic control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.

Fat LossMetabolic HealthAppetite Control GLP-1 & Metabolic

In depth

How it works

Semaglutide is a GLP-1 receptor agonist — it closely mimics a hormone your gut releases after eating. Activating GLP-1 receptors slows stomach emptying, increases insulin release when blood sugar is high, suppresses glucagon, and signals satiety centers in the brain, which is why appetite reduction and weight loss show up alongside improved blood sugar control.

It is administered as a once-weekly subcutaneous injection, and its long half-life (roughly a week) is what allows that dosing schedule instead of daily dosing like earlier GLP-1 drugs.

What the research shows

Semaglutide is one of the most extensively studied GLP-1 drugs, with FDA approval under three brand names covering different indications: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. Cardiovascular outcome trials have also shown a reduced risk of major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Systematic reviews of adverse events consistently find gastrointestinal side effects (nausea, diarrhea) as the most common issue, occurring in a meaningful minority of patients, especially during dose escalation.

Detail

Overview

Semaglutide is used or studied for weight loss; glycemic control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.

Benefits, side effects, and protocols

Benefits list

  • Weight loss
  • glycemic control

Side effects

  • Nausea
  • GI upset

Vendor protocol

  • None listed

Clinical protocol

  • None listed

Evidence

  • High
  • Highly effective obesity drug

Regulatory

  • Fda Approved
  • Prescription required

Research

Mechanisms

Glp1 Receptor Agonist

Evidence notes

  • High
  • Highly effective obesity drug

Administration

InjectableIntravenous

Research links

Contraindications

  • None listed

Components

  • None listed

Regulatory data

  • Fda Approved
  • Prescription required

Aliases

  • None listed

Used in these stacks

Related compounds

Half-life

How long does Semaglutide stay in your system?

Half-life ≈ 1 week — see what remains after any number of days, and when it is practically cleared.

Open the calculator

Guides that cover Semaglutide

Are peptides legal? What the FDA actually says

BPC-157, TB-500, CJC-1295 and ipamorelin: what the FDA has actually published about each, why “removed from Category 2” does not mean cleared, and what is still unlawful to compound.

mg, mcg and “units”: peptide dosing conversions explained

A “unit” on an insulin syringe is a volume, not an amount of drug. Here is how mg, mcg, mL and units relate — and why copying someone else’s unit count is the most dangerous shortcut in peptides.

Compounded semaglutide and tirzepatide: what changed

The shortages ended, and with them the enforcement discretion that allowed mass compounding of semaglutide and tirzepatide. What FDA actually said, with the dates, and what remains permitted.

Semaglutide vs tirzepatide: what the head-to-head trial found

SURMOUNT-5 compared them directly over 72 weeks: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide. What that number does and does not settle.

What happens when you stop a GLP-1

One year after semaglutide was withdrawn, participants had regained two-thirds of the weight they lost, and their cardiometabolic gains reverted. The withdrawal trials, read honestly.

Muscle loss on GLP-1s: what the evidence shows

A 2026 meta-analysis found lean mass falls in absolute terms on GLP-1 drugs while rising as a proportion of body weight. Both statements are true, and they explain the entire argument.

Microdosing GLP-1s: what is actually known

Microdosing semaglutide or tirzepatide is widely discussed and has never been tested in a randomised trial. Here is what exists, what does not, and why the distinction matters.

“Ozempic face”: what it is and what causes it

Facial gauntness after GLP-1 weight loss is caused by the weight loss, not by the drug. The same appearance follows rapid loss by any means — which is what the term obscures.

Terminology on this page

Concepts from the glossary that come up around Semaglutide.

Frequently asked questions

Is semaglutide FDA approved?

Yes. Semaglutide has three FDA-approved brand formulations: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management in adults with obesity or overweight with a weight-related condition.

How does semaglutide cause weight loss?

It activates GLP-1 receptors that slow gastric emptying and signal satiety in the brain, reducing appetite and food intake, while also improving insulin secretion and blood sugar regulation.

What is the most common side effect of semaglutide?

Gastrointestinal side effects — nausea, vomiting, and diarrhea — are the most frequently reported, and tend to be most noticeable during dose escalation.

What's the difference between semaglutide and tirzepatide?

Semaglutide activates only the GLP-1 receptor, while tirzepatide is a dual agonist that also activates the GIP receptor. Head-to-head trials have generally shown tirzepatide producing greater average weight loss, though individual response varies.

Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations. Sourcing Semaglutide? Check your source before you use anything.